• Consensus Rating: Reduce
  • Consensus Price Target: $10.50
  • Forecasted Upside: 50.00%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.00
▲ +0.03 (0.43%)

This chart shows the closing price for GRFS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Grifols Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRFS

Analyst Price Target is $10.50
▲ +50.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Grifols in the last 3 months. The average price target is $10.50, with a high forecast of $10.50 and a low forecast of $10.50. The average price target represents a 50.00% upside from the last price of $7.00.

This chart shows the closing price for GRFS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 3 polled investment analysts is to reduce stock in Grifols. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/18/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/12/2024Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellLow
12/5/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$10.00 ➝ $10.50Low
8/29/2023Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
4/12/2023Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
3/3/2023Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
2/16/2023BarclaysUpgradeUnderweight ➝ Equal WeightLow
2/6/2023AlphaValueUpgradeBuyLow
1/18/2023Jefferies Financial GroupUpgradeHold ➝ BuyLow
12/5/2022Morgan StanleyUpgradeEqual Weight ➝ OverweightN/A
11/25/2022Credit Suisse GroupInitiated CoverageNeutral ➝ NeutralLow
11/21/2022BarclaysBoost Target€8.00 ➝ €9.00Low
10/25/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold€16.00 ➝ €10.00Low
10/24/2022BarclaysLower TargetUnderweight ➝ Underweight€16.00 ➝ €8.00Low
10/10/2022Morgan StanleyLower Target€20.00 ➝ €13.00Low
9/14/2022JPMorgan Chase & Co.Lower Target€11.50 ➝ €10.30Low
8/2/2022Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold€17.00 ➝ €16.00Low
7/25/2022Jefferies Financial GroupInitiated CoverageHoldLow
7/15/2022Berenberg BankBoost TargetBuy ➝ Buy€20.15 ➝ €20.30Low
6/28/2022Berenberg BankLower TargetBuy ➝ Buy€21.40 ➝ €20.60Low
4/8/2022Morgan StanleyInitiated CoverageEqual WeightLow
3/3/2022Berenberg BankLower Target€21.60 ➝ €21.40High
1/4/2022JPMorgan Chase & Co.Lower Target€15.00 ➝ €11.00Low
11/4/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldMedium
10/19/2021BarclaysDowngradeOverweight ➝ UnderweightMedium
10/6/2021CitigroupUpgradeNeutral ➝ BuyHigh
8/4/2021Credit Suisse GroupReiterated RatingOutperformLow
8/4/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
6/28/2021BarclaysReiterated RatingOverweightLow
6/14/2021Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyMedium
4/27/2021Berenberg BankReiterated RatingBuyMedium
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
3/23/2021Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
3/11/2021HSBCUpgradeHold ➝ BuyHigh
3/10/2021Morgan StanleyReiterated RatingOverweightHigh
3/2/2021Credit Suisse GroupReiterated RatingNeutralLow
3/2/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/12/2021Berenberg BankReiterated RatingBuyLow
1/22/2021BarclaysReiterated RatingOverweightLow
1/20/2021Credit Suisse GroupReiterated RatingNeutralLow
1/13/2021Morgan StanleyReiterated RatingOverweightLow
12/9/2020Morgan StanleyReiterated RatingOverweightLow
11/6/2020Morgan StanleyReiterated RatingOverweightLow
10/30/2020Berenberg BankReiterated RatingBuyLow
10/1/2020CitigroupUpgradeSell ➝ NeutralLow
9/30/2020Morgan StanleyReiterated RatingOverweightLow
7/21/2020Berenberg BankReiterated RatingBuyLow
6/23/2020Morgan StanleyReiterated RatingOverweightLow
6/10/2020Berenberg BankReiterated RatingBuyMedium
6/9/2020CitigroupDowngradeNeutral ➝ SellMedium
6/9/2020HSBCUpgradeReduce ➝ HoldMedium
6/1/2020BarclaysReiterated RatingOverweightLow
4/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
3/27/2020Kepler Capital MarketsReiterated RatingHoldMedium
3/25/2020CitigroupDowngradeBuy ➝ NeutralLow
3/6/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
3/1/2020Kepler Capital MarketsReiterated RatingHoldHigh
12/12/2019William BlairReiterated RatingOutperformLow
12/9/2019Banco SabadellUpgradeSell ➝ BuyMedium
10/30/2019Berenberg BankUpgradeBuyLow
10/28/2019SantanderUpgradeHold ➝ BuyLow
6/27/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$21.00 ➝ $22.50High
(Data available from 6/14/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/17/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/17/2023
  • 5 very positive mentions
  • 25 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
1/16/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/15/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
3/16/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/15/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/15/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/14/2024

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Grifols logo
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Read More

Today's Range

Now: $7.00
Low: $6.90
High: $7.02

50 Day Range

MA: $6.98
Low: $6.27
High: $7.70

52 Week Range

Now: $7.00
Low: $5.30
High: $12.15

Volume

689,899 shs

Average Volume

2,350,884 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Grifols?

The following Wall Street sell-side analysts have issued stock ratings on Grifols in the last twelve months: Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, and StockNews.com.
View the latest analyst ratings for GRFS.

What is the current price target for Grifols?

1 Wall Street analysts have set twelve-month price targets for Grifols in the last year. Their average twelve-month price target is $10.50, suggesting a possible upside of 50.0%. JPMorgan Chase & Co. has the highest price target set, predicting GRFS will reach $10.50 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $10.50 for Grifols in the next year.
View the latest price targets for GRFS.

What is the current consensus analyst rating for Grifols?

Grifols currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for GRFS.

What other companies compete with Grifols?

How do I contact Grifols' investor relations team?

Grifols' physical mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company's listed phone number is (493) 571-0221 and its investor relations email address is [email protected]. The official website for Grifols is www.grifols.com. Learn More about contacing Grifols investor relations.